14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
ABVC vs VVOS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ABVC carries a Unified Composite Score of 47.4/100 (HOLD) at $0.87 (N/M Forward P/E, 0.0% operating margin), whereas VVOS carries 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin).
Technical & Structure Timing Caution: ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABVC vs VVOS. Trailing 12-month operating profitability (ABVC 0.0% vs VVOS -107.9%) and valuation multiples (ABVC N/M vs VVOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ABVC vs VVOS Key Questions & Quantitative Answers
As of Nov 20, 2026, ABVC BioPharma, Inc. (ABVC) is the stronger overall head-to-head candidate over Vivos Therapeutics, Inc. (VVOS) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). ABVC carries a Unified Composite Score of 47.4/100 (HOLD) at $0.87 (N/M Forward P/E, 0.0% operating margin), whereas VVOS carries 36.4/100 (SELL) at $0.05 (N/M Forward P/E, -107.9% operating margin). Technical & Structure Timing Caution: ABVC trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 35.2); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABVC leads the Growth & Scale pillar: ABVC posts +104.5% YoY revenue growth and +0.0% YoY earnings growth on $797,916 TTM revenue (100.0% gross margin, 0.0% operating margin), compared with VVOS at +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin). On trailing 12-month operating scale, ABVC generates $797,916 in USD-normalized revenue versus $21M for VVOS. In operating R&D and SG&A reinvestment, ABVC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VVOS.
VVOS screens cheaper on headline valuation multiples. ABVC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.9x EV/Revenue (unreported EBITDA margin), whereas VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABVC (-52.7% ROE) versus VVOS (-8585.3% ROE) capital efficiency.
In options market volatility and institutional positioning, ABVC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.24β · 44% Vol realized risk). By comparison, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.